Search

/DISREGARD RELEASE: YS Biopharma/

YS Biopharma

2023-12-21 05:15 2565

We are advised by YS Biopharma Co., Ltd. (NASDAQ:YS) that journalists and other readers should disregard the news release, "YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023", issued on December 20, 2023 by YS Biopharma over PR Newswire, as the release contained erroneous information.

Source: YS Biopharma

Related Stocks:

NASDAQ:YS

Keywords: Biotechnology Computer/Electronics Health Care/Hospital Medical/Pharmaceuticals

Media Room more

LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

2024-10-29 20:30

2147

LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine

2024-10-25 20:30

1816

LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

2024-10-08 20:30

3083

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

2024-09-27 19:00

1490

Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024

2024-09-10 20:00

3027

LakeShore Biopharma Announces Leadership Transitions

2024-09-04 20:00

1386

Related News

SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024

2024-11-21 18:30

783

111, Inc. to Participate in Fireside Chat with Water Tower Research on December 6, 2024

2024-11-21 18:00

809

DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation

2024-11-21 13:01

922

FDA Granted Orphan Drug Designation of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs, for Treatment of Neuroendocrine Cancer

2024-11-22 16:00

660

Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity

2024-11-22 12:14

972

Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology

2024-11-22 10:27

1020